AbbVie
AbbVie is a global biopharmaceutical company that focuses on discovering, developing, manufacturing, and selling advanced therapies for complex and serious diseases. Established in 2013 as a spin-off from Abbott Laboratories, AbbVie operates in multiple therapeutic areas including immunology, oncology, and neuroscience. The company markets a diverse portfolio of products, such as HUMIRA for autoimmune diseases, SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis, and IMBRUVICA for various cancers. AbbVie also offers treatments for chronic hepatitis C, respiratory diseases in infants, and hormonal therapies. In addition to its proprietary drugs, AbbVie Ventures, its venture capital arm, invests in emerging biotech and pharmaceutical companies, particularly in early-stage development within areas like immunology and cardiology. With a workforce of approximately 29,000, AbbVie markets its medicines in over 175 countries worldwide and collaborates with several biotechnology firms to enhance its research and development capabilities.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.